TD Cowen Reaffirms “Hold” Rating for Alpine Immune Sciences (NASDAQ:ALPN)

TD Cowen reissued their hold rating on shares of Alpine Immune Sciences (NASDAQ:ALPN) in a report issued on Tuesday, Benzinga reports.

Several other equities research analysts have also recently commented on the stock. Oppenheimer reaffirmed an outperform rating and issued a $44.00 target price (up from $33.00) on shares of Alpine Immune Sciences in a research report on Tuesday, March 19th. Wolfe Research reaffirmed a peer perform rating on shares of Alpine Immune Sciences in a research report on Thursday, April 11th. Morgan Stanley reaffirmed an equal weight rating and issued a $65.00 target price (up from $47.00) on shares of Alpine Immune Sciences in a research report on Thursday, April 11th. Royal Bank of Canada reaffirmed a sector perform rating and issued a $65.00 target price (up from $41.00) on shares of Alpine Immune Sciences in a research report on Thursday, April 11th. Finally, Leerink Partnrs cut shares of Alpine Immune Sciences from an outperform rating to a market perform rating in a research report on Thursday, April 11th. Eight equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of Hold and a consensus price target of $50.33.

Alpine Immune Sciences Stock Down 0.0 %

Shares of ALPN opened at $64.43 on Tuesday. The stock has a market capitalization of $4.22 billion, a P/E ratio of -100.67 and a beta of 1.14. The firm has a fifty day simple moving average of $39.38 and a two-hundred day simple moving average of $24.43. Alpine Immune Sciences has a twelve month low of $6.71 and a twelve month high of $64.57.

Alpine Immune Sciences (NASDAQ:ALPN) last announced its quarterly earnings results on Monday, March 18th. The biotechnology company reported $0.15 earnings per share for the quarter, beating the consensus estimate of ($0.32) by $0.47. The business had revenue of $30.85 million during the quarter, compared to analysts’ expectations of $6.90 million. Alpine Immune Sciences had a negative net margin of 54.66% and a negative return on equity of 15.54%. Sell-side analysts expect that Alpine Immune Sciences will post -1.74 EPS for the current fiscal year.

Institutional Trading of Alpine Immune Sciences

Large investors have recently made changes to their positions in the stock. Allspring Global Investments Holdings LLC grew its stake in shares of Alpine Immune Sciences by 745.5% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 1,488 shares of the biotechnology company’s stock worth $28,000 after acquiring an additional 1,312 shares during the period. Royal Bank of Canada grew its stake in shares of Alpine Immune Sciences by 99.1% in the second quarter. Royal Bank of Canada now owns 2,642 shares of the biotechnology company’s stock worth $27,000 after acquiring an additional 1,315 shares during the period. ADAR1 Capital Management LLC bought a new stake in shares of Alpine Immune Sciences in the fourth quarter worth approximately $58,000. AJOVista LLC bought a new stake in shares of Alpine Immune Sciences in the fourth quarter worth approximately $64,000. Finally, Public Employees Retirement System of Ohio bought a new stake in shares of Alpine Immune Sciences in the third quarter worth approximately $35,000. 75.17% of the stock is currently owned by institutional investors.

Alpine Immune Sciences Company Profile

Alpine Immune Sciences, Inc operates as a clinical-stage biopharmaceutical company. It focuses on the discovery and development of immunotherapies through protein engineering technologies for treating autoimmune and inflammatory diseases. The company's product pipeline includes Povetacicept, a dual B cell cytokine antagonist, which is in Phase 2 clinical trial for the treatment of multiple autoimmune and inflammatory diseases; and Acazicolcept, a dual inhibitor of the CD28 and ICOS T cell costimulatory pathways that is in preclinical trial for the treatment of systemic lupus erythematosus.